S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
NSPR · InspireMD Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$0.44
-0.01
(-2.20%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.44
$0.44
$0.46
52-WEEK RANGE
$0.44
$0.46
$2.54
What's happening
- NSPR is down 2.20% today, trading at $0.44. — Live quote
- It's trading within 3% of its 52-week low ($0.46). (Finnhub fundamentals)
- Volume today (14,496) is well below its 3-month average of 95,440. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.17 actual vs. $-0.20 estimated (+16.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NSPR
-73.70%
vs S&P 500
-86.55%
1-YEAR RETURN
NSPR
-80.24%
vs S&P 500
-96.46%
6-MONTH RETURN
NSPR
-63.71%
3-MONTH RETURN
NSPR
-34.97%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.17
Est. $-0.20
BEAT +16.7%
2026-04-26 (Q1 2026)
$-0.16
Est. $-0.18
BEAT +12.9%
2026-01-26 (Q4 2025)
$-0.14
Est. $-0.20
BEAT +29.0%
2025-10-26 (Q3 2025)
$-0.17
Est. $-0.20
BEAT +14.5%
Valuation Measures & Ratios
Enterprise Value4$6.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)2.01
Price / Book71.04
EV4 / Revenue0.61
EV4 / EBITDA—
Profit Margin-484.11%
Operating Margin-494.03%
Return on Equity (ROE8)-107.96%
Return on Assets (ROA9)-84.31%
Avg Volume (3M)95,440
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $59.0M | $136.0M | $180.2M | $116.3M | — |
| P/E | -1.09 | -2.68 | -4.01 | -2.90 | — |
| Price/Sales | 6.23 | 14.74 | 23.58 | 16.97 | — |
| Price/Book | 1.87 | 3.12 | 2.81 | 5.75 | — |
| EV/Revenue | 4.63 | 13.51 | 15.28 | 15.29 | — |
| ROE | -170.96% | -116.27% | -70.05% | -198.17% | — |
| ROA | -120.68% | -89.81% | -57.24% | -120.32% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short22,466
Change from Prior Settlement-11.43%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-23; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -0.4% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -484.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is -80.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NSPR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $3.4M | $2.5M | $1.8M | $1.5M | $1.8M | $1.7M | $1.5M |
| Gross profit | -$774.0K | $687.0K | $864.0K | $313.0K | $292.0K | $414.0K | $331.0K | $292.0K |
| Operating income | -$14.4M | -$14.0M | -$13.1M | -$13.0M | -$11.5M | -$8.5M | -$8.3M | -$7.4M |
| Net income | -$14.3M | -$13.7M | -$12.7M | -$13.2M | -$11.2M | -$7.9M | -$7.9M | -$7.0M |
| EPS (diluted) | $-0.17 | $-0.16 | $-0.17 | $-0.26 | $0.22 | $-0.16 | $-0.22 | $-0.21 |
| EPS (basic) | $-0.17 | $-0.16 | $-0.17 | $-0.26 | $0.22 | $-0.16 | $-0.22 | $-0.21 |
| Operating margin | -$816 | -$411 | -$517 | -$732 | -$750 | -$468 | -$475 | -$491 |
| Net margin | -$809 | -$403 | -$504 | -$740 | -$730 | -$436 | -$455 | -$465 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $44.6M | $56.5M | $69.4M | $78.5M | $33.3M | $38.7M | $46.8M | $50.5M |
| Total liabilities | $13.1M | $12.9M | $14.2M | $14.4M | $13.1M | $10.3M | $10.7M | $9.1M |
| Stockholders' equity | $31.5M | $43.6M | $55.2M | $64.1M | $20.2M | $28.3M | $36.1M | $41.4M |
| Total current assets | $36.6M | $48.6M | $61.5M | $70.4M | $25.5M | $32.1M | $40.5M | $46.4M |
| Total current liabilities | $9.6M | $9.4M | $10.7M | $10.8M | $9.1M | $7.4M | $7.7M | $7.3M |
| Cash & equivalents | $15.1M | $11.4M | $8.9M | $63.4M | $11.5M | $12.4M | $18.9M | $15.8M |
| Marketable securities (current) | $15.3M | $30.2M | $45.3M | — | $7.9M | $13.7M | $15.7M | $24.6M |
| Accounts receivable | $1.8M | $2.4M | $2.2M | $2.0M | $1.6M | $1.6M | $1.6M | $1.5M |
| Inventory | $2.7M | $3.0M | $3.4M | $3.6M | $3.1M | $2.8M | $2.6M | $2.4M |
| Property, plant & equipment | $3.9M | $3.7M | $3.6M | $3.4M | $3.1M | $2.7M | $2.4M | $1.9M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accrued liabilities | $1.0M | $1.1M | $1.5M | $735.0K | $1.0M | $821.0K | $1.3M | $1.4M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $5.0K | $4.0K | $4.0K | $4.0K | $3.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$330.3M | -$316.0M | -$302.3M | -$290.5M | -$277.8M | -$264.7M | -$253.5M | -$244.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.9M | -$12.3M | -$9.3M | -$8.6M | -$8.3M | -$8.8M | -$6.8M | -$5.7M |
| Investing cash flow | $14.7M | $14.8M | -$45.1M | $7.6M | $5.3M | $1.7M | $8.2M | -$5.9M |
| Financing cash flow | — | — | $0 | $52.9M | $2.1M | $506.0K | $1.6M | -$965.0K |
| Free cash flow | -$11.2M | -$12.5M | -$9.7M | -$9.0M | -$8.9M | -$9.2M | -$7.1M | -$6.1M |
| Capital expenditures | $330.0K | $194.0K | $398.0K | $329.0K | $576.0K | $359.0K | $311.0K | $421.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $2.2M | $2.1M | $2.8M | $3.5M | $3.2M | $2.7M | $2.3M | $2.4M |
| Change in accounts receivable | -$565.0K | $213.0K | $207.0K | $369.0K | $12.0K | $8.0K | $42.0K | $223.0K |
| Change in inventory | -$335.0K | -$360.0K | -$211.0K | $553.0K | $232.0K | $252.0K | $125.0K | $239.0K |
| Purchases of investments | — | — | $45.1M | $0 | $4.8M | $6.9M | $0 | $12.5M |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $9.0M | $7.0M | $6.2M | $5.2M | $4.5M |
| Gross profit | $2.6M | $1.5M | $1.8M | $1.1M | $754.0K |
| Operating income | -$49.6M | -$33.5M | -$21.1M | -$18.7M | -$14.7M |
| Net income | -$48.8M | -$32.0M | -$19.9M | -$18.5M | -$14.9M |
| EPS (diluted) | $-0.76 | $-0.76 | $-0.82 | $-2.35 | — |
| EPS (basic) | $-0.76 | $-0.76 | $-0.82 | $-2.35 | $-2.03 |
| Operating margin | -$553 | -$478 | -$341 | -$362 | -$327 |
| Net margin | -$543 | -$457 | -$321 | -$358 | -$332 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $69.4M | $46.8M | $47.6M | $24.7M | $39.7M |
| Total liabilities | $14.2M | $10.7M | $8.1M | $7.3M | $6.2M |
| Stockholders' equity | $55.2M | $36.1M | $39.5M | $17.4M | $33.5M |
| Total current assets | $61.5M | $40.5M | $44.2M | $21.3M | $37.1M |
| Total current liabilities | $10.7M | $7.7M | $6.0M | $5.1M | $4.3M |
| Cash & equivalents | $8.9M | $18.9M | $9.6M | $4.6M | $12.0M |
| Marketable securities (current) | $45.3M | $15.7M | $29.4M | — | — |
| Accounts receivable | $2.2M | $1.6M | $1.8M | $1.0M | $1.2M |
| Inventory | $3.4M | $2.6M | $2.1M | $1.6M | $1.1M |
| Property, plant & equipment | $3.6M | $2.4M | $1.1M | $917.0K | $632.0K |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — |
| Accrued liabilities | $1.5M | $1.3M | $1.1M | $554.0K | $632.0K |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $4.0K | $3.0K | $2.0K | $1.0K | $1.0K |
| Retained earnings | -$302.3M | -$253.5M | -$221.5M | -$201.6M | -$183.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$35.1M | -$21.9M | -$16.4M | -$15.5M | -$13.2M |
| Investing cash flow | -$30.6M | $12.6M | -$16.1M | $8.4M | -$22.5M |
| Financing cash flow | $55.6M | $18.5M | $37.5M | -$140.0K | $35.0M |
| Free cash flow | -$36.8M | -$23.3M | -$16.8M | -$16.0M | -$13.6M |
| Capital expenditures | $1.7M | $1.4M | $381.0K | $473.0K | $344.0K |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $12.3M | $10.1M | $4.5M | $2.4M | $1.6M |
| Change in accounts receivable | $596.0K | -$232.0K | $770.0K | -$190.0K | $748.0K |
| Change in inventory | $826.0K | $464.0K | $485.0K | $478.0K | -$272.0K |
| Purchases of investments | $56.8M | $14.4M | $34.6M | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NSPR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-27 to 2026-05-27
Recent transactions
- Insiders have net bought 295,993 shares over the last 182 days, across 11 purchases and 1 sale.
- Most recent: Stuka Paul (Director) — Open market purchase of 20,000 shares on 2026-05-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)318,771 sh(11 txns)
Sales (open market)22,778 sh(1 txns)
Net Shares+295,993
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Stuka Paul | Director | Open market purchase | 2026-05-27 | 20,000 |
| Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2026-05-19 | 22,778 |
| Slosman Marvin | CEO and President | Open market purchase | 2026-05-12 | 21,000 |
| Ward Scott R. | Director | Open market purchase | 2026-05-07 | 73,255 |
| ROUBIN GARY S | Director | Open market purchase | 2026-05-07 | 90,000 |
| Tommasoli Andrea | Chief Operating Officer | Grant / award | 2026-01-14 | 226,695 |
| Lawless Michael A | Chief Financial Officer | Grant / award | 2026-01-14 | 226,695 |
| Dearen Danny L. | Director | Grant / award | 2026-01-14 | 44,030 |
| COHEN RAYMOND W | Director | Grant / award | 2026-01-14 | 44,030 |
| BERMAN MICHAEL | Director | Grant / award | 2026-01-14 | 88,053 |
| Arnold Kathryn | Director | Grant / award | 2025-12-30 | 55,556 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-27 | Stuka Paul | Director | Open market purchase | 20,000 | $0.88 |
| 2026-05-19 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 22,778 | $1.01 |
| 2026-05-14 | Stuka Paul | Director | Open market purchase | 5,000 | $1.15 |
| 2026-05-13 | Stuka Paul | Director | Open market purchase | 10,000 | $1.16 |
| 2026-05-12 | Slosman Marvin | CEO and President | Open market purchase | 21,000 | $1.20 |
| 2026-05-11 | Stuka Paul | Director | Open market purchase | 10,000 | $1.19 |
| 2026-05-08 | Stuka Paul | Director | Open market purchase | 65,626 | $1.16 |
| 2026-05-07 | Ward Scott R. | Director | Open market purchase | 73,255 | $1.15 |
| 2026-05-07 | Stuka Paul | Director | Open market purchase | 6,378 | $1.15 |
| 2026-05-07 | ROUBIN GARY S | Director | Open market purchase | 90,000 | $1.18 |
| 2026-05-06 | Ward Scott R. | Director | Open market purchase | 15,995 | $1.15 |
| 2026-05-06 | Stuka Paul | Director | Open market purchase | 1,517 | $1.12 |
| 2026-02-02 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,941 | $1.59 |
| 2026-02-02 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,000 | $1.60 |
| 2026-01-30 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,900 | $1.63 |
| 2026-01-29 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 5,000 | $1.65 |
| 2026-01-28 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 12,395 | $1.65 |
| 2026-01-27 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 4,781 | $1.66 |
| 2026-01-22 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 8,411 | $1.57 |
| 2026-01-21 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 17,593 | $1.62 |
| 2026-01-20 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,955 | $1.59 |
| 2026-01-16 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,250 | $1.61 |
| 2026-01-15 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,909 | $1.58 |
| 2026-01-14 | Ward Scott R. | Director | Grant / award | 88,053 | $0.00 |
| 2026-01-14 | Tommasoli Andrea | Chief Operating Officer | Grant / award | 226,695 | $0.00 |
| 2026-01-14 | Stuka Paul | Director | Grant / award | 132,076 | $0.00 |
| 2026-01-14 | Slosman Marvin | CEO and President | Grant / award | 1,114,792 | $0.00 |
| 2026-01-14 | ROUBIN GARY S | Director | Grant / award | 88,053 | $0.00 |
| 2026-01-14 | Lawless Michael A | Chief Financial Officer | Grant / award | 226,695 | $0.00 |
| 2026-01-14 | Gleason Shane Thomas | Chief Commercial Officer | Grant / award | 453,390 | $0.00 |
| 2026-01-14 | Dearen Danny L. | Director | Grant / award | 44,030 | $0.00 |
| 2026-01-14 | COHEN RAYMOND W | Director | Grant / award | 44,030 | $0.00 |
| 2026-01-14 | BERMAN MICHAEL | Director | Grant / award | 88,053 | $0.00 |
| 2025-12-30 | Arnold Kathryn | Director | Grant / award | 55,556 | $0.00 |
| 2025-12-09 | Stuka Paul | Director | Open market purchase | 5,073 | $1.81 |
| 2025-12-05 | Stuka Paul | Director | Open market purchase | 5,073 | $1.86 |
| 2025-05-30 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 7,186 | $2.51 |
| 2025-05-29 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 3,760 | $2.51 |
| 2025-05-27 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 1,572 | $2.51 |
| 2025-05-23 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,482 | $2.51 |
| 2025-02-25 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 10,000 | $3.65 |
| 2025-02-04 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 5,132 | $2.46 |
| 2025-02-03 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 7,073 | $2.51 |
| 2025-01-31 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 9,923 | $2.55 |
| 2025-01-30 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,454 | $2.51 |
| 2025-01-29 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 3,660 | $2.46 |
| 2025-01-28 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 2,476 | $2.61 |
| 2025-01-27 | Gleason Shane Thomas | Chief Commercial Officer | Open market sale | 3,858 | $2.71 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:49 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-23 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-09-21 | 8-K | 2026-09-21 | View on SEC.gov → |
| 2026-08-17 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-23 | View on SEC.gov → |
| 2026-07-23 | 8-K | 2026-07-17 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-26 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-06-03 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-05-29 | 4 | 2026-05-27 | View on SEC.gov → |
Recent news
Headlines about NSPR (InspireMD Inc.). Links open the publisher — we don’t host full articles.
-
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance · 2026-09-04 -
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-09-03 -
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know
Yahoo Finance · 2026-08-20 -
InspireMD Inc (NSPR) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges While ...
Yahoo Finance · 2026-08-17 -
InspireMD signals potential FDA decisions in Q4 2026 while targeting $9M in annual cost savings
Seeking Alpha · 2026-08-17 -
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-08-17 -
InspireMD Reports Second Quarter 2026 Financial Results
Yahoo Finance · 2026-08-17 -
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates
Yahoo Finance · 2026-08-14
No headlines in this category right now — try “All”.